ArticleFrontiers in physiology2026
Ceramidase is involved in metabolic reprogramming of fibroblasts under hypoxia conditions.
Article in Frontiers in physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Physiological metabolic reprogramming is a cells strategy to resist/counteract stress to preserve homeostasis. Hypoxia is an important stress stimulus that can promote tissue remodeling and fibrosis, in which alterations in sphingolipid metabolism may contribute to fibroblast responses. Here, we investigated the potential role of acid ceramidase (ASAH1), a key enzyme of the sphingolipid salvage pathway, in fibroblast adaptation to hypoxic stress. Methods: Human fibroblasts were exposed to hypoxia for 24, 48, and 72 hours, and metabolic and redox changes were investigated following pharmacological inhibition of acid ceramidase with D-Nmappd. These findings were complemented by analyses of publicly available bulk and single-cell RNA sequencing datasets from idiopathic pulmonary fibrosis (IPF) lungs. Results: Hypoxic fibroblasts showed metabolic remodeling involving glucose-, amino acid-, and redox-associated pathways, together with changes consistent with an adaptive antioxidant response, including alterations in the GSH/GSSG balance. Pharmacological inhibition of acid ceramidase under hypoxia was associated with changes in carnitine metabolism and long-chain fatty acid β-oxidation, reduced GSH and GSSG levels, and decreased expression of Nuclear Factor Erythroid 2-Related Factor 2 (NRF2), Superoxide dismutase 2 (SOD2), and 8-Oxoguanine DNA Glycosylase 1 (OGG1). In IPF lung tissue, ASAH1 expression was associated with glycolytic and redox-related genes. Single-cell analysis showed that ASAH1-expressing IPF fibroblasts were enriched in transcriptional programs related to hypoxic responses and oxidative stress regulation and displayed features associated with a less activated phenotype. Discussion: Overall, these findings suggest that acid ceramidase/ASAH1 is associated with fibroblast metabolic and redox adaptation to hypoxic stress and may influence fibroblast activation in IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.